Peptide-mediated intravesical delivery of therapeutic and diagnostic agents
a technology applied in the field of peptide-mediated intravesical delivery of therapeutic and diagnostic agents, can solve the problems of hampered drug development of this approach, unable to achieve the effect of non-cancerous diseased condition, and relying on concentration gradients to achieve the effect of facilitating the delivery of the agen
a technology applied in the field of peptide-mediated intravesical delivery of therapeutic and diagnostic agents, can solve the problems of hampered drug development of this approach, unable to achieve the effect of non-cancerous diseased condition, and relying on concentration gradients to achieve the effect of facilitating the delivery of the agen
US20180333496A1Inactive Publication Date: 2018-11-22UNIVERSITY OF PITTSBURGH
Image
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
working example
[0041]The present study describes the use of a new carrier for ODN, Protamine, which has been used as a component in the delivery system for gene and ODN in the past, but not in this context [14]. Protamine is highly stable, well characterized and is used clinically as an antidote to heparin overdoses and a complexing agent for insulin in long-acting preparations [15]. It has, however, been reported to have toxic effects when instilled into bladder at relatively higher concentration [21-23].
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The present invention relates to compositions comprising therapeutic and / or diagnostic anionic agents together with cationic peptides and their use in methods for delivering the anionic agents to bladder cells.
Description
PRIORITY CLAIM[0001]This application is a division of U.S. patent application Ser. No. 14 / 846,536, filed Sep. 4, 2015, which claims priority to U.S. Provisional Application No. 62 / 046,585 filed Sep. 5, 2014, the contents of which are hereby incorporated by reference in its entirety herein.GRANT INFORMATION[0002]This invention was made with government support under Grant No. DK088836 awarded by the National Institutes of Health. The government has certain rights in the invention.INTRODUCTION[0003]The present invention relates to methods and compositions for administering agents to cells in the bladder, whereby a cationic peptide or a mixture of cationic peptides is used to deliver an anionic therapeutic or diagnostic agent.BACKGROUND OF THE INVENTION[0004]Introduction of short strands of antisense DNA with sequences complementary to the mRNA encoding a particular protein inside the cell is being explored as a therapeutic approach [1]. The inserted antisense oligonucleotide (“ODN”) bi...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
22 Nov 2018
Publication
US20180333496A1
- IPC
- A61K47/42; A61K31/7088; A61K47/64
- CPC
- A61K31/7088; A61K47/645; A61K47/42; C12N15/113; A61K49/0002; A61K47/6807
- Inventors
- TYAGI, PRADEEP; YOSHIMURA, NAOKI